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Accumulating evidence has suggested a role for
p53 activation in various age-associated conditions.
Here, we identified a crucial role of endothelial p53
activation in the regulation of glucose homeostasis.
Endothelial expression of p53 was markedly upregu-
lated when mice were fed a high-calorie diet. Disrup-
tion of endothelial p53 activation improved dietary
inactivation of endothelial nitric oxide synthase that
upregulated the expression of peroxisome prolifera-
tor-activated receptor-g coactivator-1a in skeletal
muscle, thereby increasingmitochondrial biogenesis
and oxygen consumption. Mice with endothelial
cell-specific p53 deficiency fed a high-calorie diet
showed improvement of insulin sensitivity and less
fat accumulation, compared with control littermates.
Conversely, upregulation of endothelial p53 caused
metabolic abnormalities. These results indicate that
inhibition of endothelial p53 could be a novel thera-
peutic target to block the vicious cycle of cardiovas-
cular and metabolic abnormalities associated with
obesity.
INTRODUCTION
The transcriptional factor p53 is a tumor suppressor protein that
is activated by various stresses, such as oncogenic stimuli, hyp-
oxia, and oxidative stress (Serrano and Blasco, 2001; Stewart
and Weinberg, 2006). It is thought to be a defensive mechanism
against malignant transformation. Accumulating evidence has
suggested a role of p53 activation in various age-associated
conditions, including vascular senescence (Chen and Goligor-
sky, 2006; Minamino and Komuro, 2007, 2008), heart failure
(McTernan et al., 2003; Plutzky, 2011; Sano et al., 2007), and dia-
betes (Chang et al., 2004; Minamino et al., 2009). AtherogenicCfactors like oxidized low density lipoprotein and angiotensin II
have been shown to upregulate cell-cycle regulators, includ-
ing p53, contributing to vascular dysfunction (Minamino and
Komuro, 2007, 2008). It has also been reported that vascular
p53 is activated in patients with diabetes (Brodsky et al., 2004;
Montooth et al., 2003; Orimo et al., 2009) and the development
of cardiovascular complications is accelerated by this disease
(Beckman et al., 2002; Puigserver et al., 1998). However, it re-
mains unclear whether activation of vascular p53 contributes
to metabolic abnormalities associated with obesity.
Central obesity and associated inflammation of visceral fat are
thought to play a major role in the development of insulin resis-
tance (Gordon, 2007; Hotamisligil, 2006). There is evidence
that microvascular dysfunction also promotes insulin resistance
by impairing glucose uptake into skeletal muscle (Clark, 2008;
Jonk et al., 2007). The initial human study demonstrated that in-
sulin-stimulated vasodilation contributes significantly to insulin-
mediated glucose uptake, which is impaired in patients with
type 2 diabetes (Laakso et al., 1990). Subsequent studies have
shown that an insulin-stimulated increase in the number of
perfused capillaries in the skeletal muscles, a phenomenon
known as capillary recruitment, has a more important influence
on glucose uptake than the insulin-induced increase of total
blood flow (Clark et al., 2003). In individuals with insulin resis-
tance, the influence of insulin on microvascular perfusion is
markedly impaired (Czernichow et al., 2010; Muris et al., 2012),
suggesting that insulin regulates glucose uptake and insulin
sensitivity via a feedforward mechanism. Consistent with this
notion, capillary recruitment and glucose tolerance are impaired
in mice with endothelial deletion of Irs-2 (Kubota et al., 2011). In
contrast, mice with endothelial cell-specific insulin receptor
knockout do not exhibit glucose intolerance (Vicent et al.,
2003). Moreover, the development of microvascular dysfunction
precedes the onset of insulin resistance (Clark, 2008), indicating
that additional mechanisms may contribute to vascular dysfunc-
tion associated with diabetes.
In the present study, we investigated the role of endothelial
p53 in glucose homeostasis. We found that a high-calorie dietell Reports 7, 1691–1703, June 12, 2014 ª2014 The Authors 1691
Figure 1. Upregulation of Endothelial p53
under Diabetic Conditions
(A) Human umbilical vein endothelial cells
(HUVECs) transfected with siRNA targeting p53
(sip53) or control siRNA (siControl) were treated
with high glucose (HG) or with palmitic acid (PA) for
24 hr. Expression of p53 and p21 was examined
by western blot analysis.
(B) Real-time PCR assessing the expression of
CDKN1A (p21) in HUVECs prepared as in Fig-
ure 1A (n = 3).
(C and D) Immunohistochemistry for p53 (C) and
real-time PCR assessing expression of Cdkn1a
(p21) (D) in the aorta of mice fed a normal chow
(Chow) or a high-fat/high-sucrose (HFHS) diet
(n = 5). Arrows indicate p53-positive endothelial
cells (Brown).
(E) Immunohistochemistry for isolection B4
(Brown), a marker of endothelial cells, and p53
(Red) in lung and quadricepsmuscle tissue of mice
prepared as in Figure 1C.
(F) Expression of p53 was examined by western
blot analysis in endothelial cells isolated from the
lungs and lower limb skeletal muscles of mice fed
chow or an HFHS diet. Scale bar, 20 mm. *p < 0.05,
**p < 0.01. Data are shown as the means ± SEM.increased endothelial expression of p53. Despite no difference
of food intake, deletion of endothelial p53 significantly improved
fat accumulation and insulin resistance in a dietary obesity
model. In addition, endothelial p53 negatively regulated the
activation of endothelial nitric oxide synthase (eNOS), which
modulates the expression of peroxisome proliferator-activated
receptor-g coactivator-1a (Pgc-1a) in skeletal muscle, so mito-
chondrial biogenesis was increased by endothelial p53 deletion
in this model. Furthermore, we found that endothelial p53 defi-
ciency led to an increase of glucose uptake into skeletal muscle
by upregulating glucose transporter (Glut) 1 expression in endo-
thelial cells. Conversely, overexpression of endothelial p53 led to
impairment of glucose metabolism. These findings indicate that
inhibition of endothelial p53 improves metabolic abnormalities
by increasing energy consumption and glucose uptake. They
also suggest that dietary activation of endothelial p53 may be
a cause of vascular dysfunction that induces insulin resistance
in diet-induced obesity.
RESULTS
Metabolic Abnormalities Increase p53 Activity in
Endothelial Cells
Features of the diabetic state, such as hyperglycemia and hyper-
lipidemia, have been shown to cause DNA damage in endothelial
cells (Minamino and Komuro, 2007, 2008). In agreement with1692 Cell Reports 7, 1691–1703, June 12, 2014 ª2014 The Authorsthese reports, we found that exposure
of human endothelial cells to high glucose
or palmitic acid upregulated the ex-
pression of p53 protein (Figure 1A). We
also confirmed that these stimuli sig-
nificantly increased the expression ofcyclin-dependent kinase inhibitor 1a (CDKN1A, known as p21)
at both the mRNA and protein levels in a p53-dependent manner
(Figures 1A and 1B), leading to cell-cycle arrest in G1 phase (Fig-
ure S1A). Likewise, the endothelial expression of p53 protein and
Cdkn1amRNAwas upregulated in the aorta when the mice were
fed a high-fat/high sucrose diet (Figures 1C and 1D). Increased
expression of p53 was also observed in microvessels of the
lungs and skeletal muscle in mice on a high-calorie diet
(Figure 1E). We subsequently examined p53 expression in endo-
thelial cells (CD31+ CD45) isolated from these tissues and
confirmed that expression of endothelial cell-specific genes
was significantly increased in the isolated cell fractions com-
pared with whole samples or depleted fractions (Figures S1B
and S1C). Moreover, expression of p53 protein was significantly
higher in endothelial cells isolated from the tissues of mice fed a
high-calorie diet compared with cells frommice on a normal diet
(Figure 1F). These findings suggested that a high-calorie state
activates p53 in endothelial cells.
Dietary Endothelial p53 Activation Contributes to the
Development of Metabolic Abnormalities
To further investigate the role of endothelial p53 in glucose
homeostasis, we established endothelial cell-specific p53
knockout (EC-p53 KO) mice (Tie2-Cre; Trp53loxP/loxP). Expres-
sion of p53 and its target genes (including Cdkn1a) were signifi-
cantly decreased in organs with a high vascularity, including the
lungs (Figure S2A). There were no differences of body weight
and glucose metabolisms between EC-p53 KO mice and their
control littermates on a normal diet (Figures 2A and 2B). In
contrast, EC-p53 KO mice had a significantly lower body weight
compared with control mice when fed a high-calorie diet (Fig-
ure 2A). Furthermore, compared with control littermates, EC-
p53 KO mice showed improvement of insulin sensitivity and
glucose tolerance alongwith a lower plasma insulin level (Figures
2C and 2D) and less accumulation of both visceral and subcu-
taneous fat, whereas their lean mass was unchanged (Figures
2E and S2B) and there was no difference of dietary intake
between the two groups (Figure 2F). Insulin-induced phosphor-
ylation of Akt was restored in the liver, skeletal muscle, and
epididymal fat of EC-p53 KO mice (Figures S2C–S2E). Expres-
sion of proinflammatory cytokines was also downregulated in
fat tissue of EC-p53 KO mice (Figures 2G and S2F). Although
we did not find any differences of core body temperature or
locomotor activity between EC-p53 KO mice and their control
littermates (Figure 2H), oxygen consumption was significantly
increased by disruption of endothelial p53 expression (Figure 2I).
These results indicated that deletion of endothelial p53 attenu-
ates fat accumulation and weight gain due to a high-calorie
diet by increasing energy expenditure and therefore improves
metabolic abnormalities related to dietary obesity.
Because Tie2 can be expressed by hematopoietic cells
(Tang et al., 2010), we additionally established Pdgfb-Cre-ER;
Trp53loxP/loxP mice as a model of endothelial cell-specific p53
deletion. In this model, the efficiency of tamoxifen-induced Cre
recombinase activity has previously been tested with ROSA26-
lacZ reporter mice, revealing that recombination was achieved
in most of the endothelial cells of the capillaries and small arteri-
oles in adult animals (Benedito et al., 2009; Claxton et al., 2008).
Although endogenous Pdgfb is also expressed by nonendothe-
lial cells, the previous study demonstrated that the transgene
expression was endothelial cell-specific in various tissues, in-
cluding skeletal muscle (Claxton et al., 2008). We also confirmed
the endothelial cell-specific expression of the transgene in the
skeletal muscle of Pdgfb-Cre-ER; Trp53loxP/loxP mice, by local-
izing expression of enhanced green fluorescent protein that is
encoded by the transgene of these mice (Figures S2G and
S2H). In Pdgfb-Cre-ER; Trp53loxP/loxP mice, expression of p53
was significantly decreased in isolated endothelial cells, but
not in bone marrow cells (Figure S2I). When fed a high-calorie
diet, Pdgfb-Cre-ER; Trp53loxP/loxP mice showed less weight
gain, as well as improved insulin sensitivity and glucose toler-
ance, compared with their control littermates similar to Tie2-
Cre; Trp53loxP/loxP mice (Figures S2J and S2K).
We also found that glucose uptake by skeletal muscle and
brown adipose tissue was significantly increased in EC-p53 KO
mice on a high-calorie diet, but not when these mice were fed a
normal diet (Figures 2J, S2L, and S2M). These results suggest
that activation of endothelial p53 reduces the energy consump-
tion and mediates various metabolic abnormalities in diabetes.
Inhibition of p53 Activation in Endothelial Cells
Increases Mitochondrial Biogenesis in Skeletal Muscle
We next investigated the mechanisms by which inhibition of
endothelial p53 activation increased oxygen consumption in aCmodel of dietary obesity. There were no differences in the weight
of brown adipose tissue and the expression of uncoupled protein
1 between the two groups (Figures S3A and S3B). It has been
reported that skeletal muscle makes the great contribution to
energy expenditure, both at rest and during exercise (Butler
and Kozak, 2010). Several studies using genetically modified
mice have suggested that an increase of mitochondrial biogen-
esis in skeletal muscle leads to increased energy expenditure
and protection against dietary obesity (Aguilar et al., 2007; Nar-
kar et al., 2008). Accordingly, we next investigated the pheno-
typic features of skeletal muscle in EC-p53 KO mice.
It has been reported that activation of endothelial p53 leads to
various functional abnormalities, including decreased produc-
tion of nitric oxide (NO), which regulates vascular relaxation,
angiogenesis, and mitochondrial biogenesis (Arany, 2008;
Chen and Goligorsky, 2006; Leone et al., 2005; Minamino and
Komuro, 2007, 2008). We therefore hypothesized that p53-
induced inhibition of eNOS might affect oxygen consumption
in skeletal muscle. Consistent with this concept, phosphoryla-
tion of eNOS was markedly decreased in control mice fed a
high-calorie diet, and this decrease was significantly reversed
in EC-p53 KO mice (Figure 3A). Likewise, expression of p21 in
aortic endothelial cells wasmarkedly increased by a high-calorie
diet, and this increase was diminished by deletion of endothelial
p53 (Figure S3C). Because NO has been reported to induce
mitochondrial biogenesis via upregulation of PGC-1a (Lin et al.,
2002), we next examined the effect of endothelial p53 on the
expression of Pgc-1a (also known as Ppargc1a) and its regu-
lating molecules related to mitochondrial biogenesis, such as
nuclear respiratory factor (Nrf)-1 and mitochondrial transcription
factor A (Tfam) (Arany, 2008; Arany et al., 2008; Leone et al.,
2005), in skeletal muscle cells by using a coculture system. Over-
expression of p53 in endothelial cells led to a decrease of
phosphorylated eNOS (Figure 3B) that was associated with
downregulation of Ppargc1a, Nrf-1, and Tfam in cocultured
skeletal muscle cells (Figure 3C). Treatment with an NO donor
attenuated the decreased expression of Pgc-1a, Nrf-1, and
Tfam (Figure 3C). We also found that Pgc-1a expression and
the mitochondrial DNA content were significantly reduced in
the skeletal muscle of control mice on a high-calorie diet
compared with mice on a normal diet, whereas these abnormal-
ities were improved in EC-p53 KO mice (Figures 3D and 3E).
Expression of Pgc-1a-target genes related to the metabolic
pathways (in particular the fatty acid oxidation-related pathway)
was significantly increased in the skeletal muscle of EC-p53 KO
mice (Figure S3D). There was no significant difference of the
respiration rate of mitochondria isolated from skeletal muscle
between the two groups (Figure S3E). These results suggest
that endothelial p53modulates mitochondrial biogenesis in skel-
etal muscle by regulating eNOS activity.
In contrast, the vessel density in skeletal muscle and the
expression of endothelial cell-specific genes were not altered
by inhibition of endothelial p53 (Figures S3F and S3G). Laser
Doppler analysis did not detect any difference of blood flow be-
tween the two groups (Figure S3H). Moreover, microangiogra-
phy using fluorescent microspheres showed that microvascular
perfusion did not differ between the two groups before and
after insulin stimulation (Figure S3I), supporting a crucial role ofell Reports 7, 1691–1703, June 12, 2014 ª2014 The Authors 1693
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NO-induced mitochondrial biogenesis in improving the meta-
bolism of EC-p53 KO mice. These results raised the possibility
that microvascular perfusion was also regulated by NO-indepen-
dent mechanisms in EC-p53 KO mice.
To further investigate the role of eNOS, we established EC-
p53-eNOS double knockout mice (Tie2-Cre; Trp53loxP/loxP;
eNOS +/) and fed these animals a high-calorie diet. Disruption
of eNOS inhibited the increase of Pgc-1a expression and the
mitochondrial DNA content caused by endothelial p53 deletion
(Figures 3F and 3G). Consequently, there was less improvement
of metabolic abnormalities acquired by endothelial p53 deletion
in EC-p53-eNOS double knockout mice (Figure 3H).
Mechanism of the p53-Induced Decrease of eNOS
Phosphorylation in Endothelial Cells
Next, we investigated how p53 induced a decrease of eNOS
activity in endothelial cells. Previous studies have demonstrated
that the p53-binding element exists in the promoter region of
NOS3 (a gene encoding eNOS) (Mortensen et al., 1999) and
that p53 negatively regulates eNOS expression at the transcrip-
tional level (Kim et al., 2008; Kumar et al., 2011). In our models,
activation of p53 did not downregulate eNOS protein production,
but its level of phosphorylation was decreased (Figures 3A and
3B), suggesting the presence of another regulatory mechanism
for eNOS that involves phosphorylation. We therefore examined
the expression of various kinases and phosphatases that regu-
late eNOS phosphorylation (Kukreja and Xi, 2007) and found
that p53 suppressed the phosphorylation of Akt, a well-known
kinase upstream of eNOS, in endothelial cells (Figure 4A).
Conversely, phosphorylation of Akt was increased by knock-
down of p53 in human endothelial cells (Figure S4A). We also
found that the expression of phosphatase and tensin homolog
(PTEN) and pleckstrin homology-like domain, family A, member
3 (PHLDA3) was positively regulated by p53 (Figures 4B, S4A,
and S4B), both of which are known to be target genes of p53
that inhibit Akt phosphorylation in cancer cells (Cantley and
Neel, 1999; Kawase et al., 2009; Stambolic et al., 2001). Accord-
ingly, we examined the effect of deletion of these genes on
eNOS phosphorylation in endothelial cells. The p53-induced
decrease of eNOS phosphorylation was not altered by deletion
of PHLDA3 (Figure S4C), but knockdown of PTEN reversed theFigure 2. Effect of Endothelial p53-Deficiency on Glucose Metabolism
(A) Body weight of EC-p53 KO mice and their littermate controls (Control) on a no
Control-HFHS versus EC-p53KO-HFHS; yp < 0.05, yyp < 0.01, yyyp < 0.001, Contro
HFHS. The right photograph shows the appearances of EC-p53 KO mouse and
(B and C) Glucose tolerance test (GTT) and insulin tolerance test (ITT) were exa
n = 13, C).
(D) Plasma insulin levels during GTT in mice on the HFHS diet (n = 9).
(E) CT analysis of EC-p53 KOmice and littermate controls (Control) after 8 weeks o
fat and subcutaneous fat (n = 13).
(F) Food intake of EC-p53 KO mice and littermate controls (Control) on the HFHS
(G) Real-time PCR analysis forCcl2 of the epididymal fat of EC-p53 KOmice and li
(HFHS) diet (n = 3–4).
(H) Oxygen consumption of EC-p53 KOmice and littermate controls (Control) on th
phase (Light) and the dark phase (Dark) (n = 8).
(I) The core body temperature and the activity of EC-p53 KO mice and littermate
(J) Glucose uptake by skeletal muscles in lower extremities of EC-p53 KO mice a
Data are shown as the means ± SEM.
Cdownregulation of phospho-Akt and phospho-eNOS in p53-
infected cells (Figures 4A, 4C, 4D, and S4C), suggesting that
p53-induced PTEN transactivation negatively regulates the
Akt-eNOS pathway.
Endothelial p53 Negatively Regulates Glucose Uptake
into Skeletal Muscle by Downregulating GLUT1
Expression
It has been reported that disruption of Glut4 in skeletal muscle
impairs glucose uptake and induces insulin resistance (Kim
et al., 2005), whereas Pgc-1a upregulates the expression of
Glut4 (also known as Slc2a4) in skeletal myocytes (Michael
et al., 2001). Although EC-p53 KO mice had higher levels of
Pgc-1a compared with control littermates, there was no signifi-
cant difference of Glut4 expression in skeletal muscle between
the two groups (Figure 5A). It has also been reported that p53
directly suppresses tumor cell expression of glucose trans-
porters, among which GLUT1 is amajor modulator of endothelial
glucose transport into skeletal muscle (Russell and Kahn, 2007).
We found that overexpression of p53 led to downregulation of
GLUT1 (also known asSLC2A1) expression in human endothelial
cells (Figure 5B). Exposure of these cells to high glucose resulted
in the upregulation of p53 expression (Figure 1A) and inhibited
glucose transport (Figure 5C). The high glucose-induced
decrease of glucose transport in endothelial cells was improved
by knockdown of p53 (Figures 5D and S5A), and this effect was
dependent on GLUT1 expression (Figures 5D and S5B). Consis-
tent with these in vitro data, the expression of vascular Glut1
(Slc2a1) was downregulated in control mice on a high-calorie
diet, and this downregulation was reversed by disruption of
endothelial p53 (Figures 5E and S5C).
To examine the role of GLUT1 in muscle glucose transport,
we treated EC-p53 KO mice with small interfering RNA
(siRNA)-targeting Slc2a1 and analyzed glucose uptake by
skeletal muscle. We confirmed that this treatment led to signif-
icant downregulation of endothelial gene expression in various
tissues, including skeletal muscle, by using a siRNA targeting
the endothelial cell-specific gene Flk-1 (Figure S5D). We found
that knockdown of endothelial Glut1 significantly inhibited
glucose uptake by skeletal muscle in EC-p53 KO mice (Fig-
ure 5F), suggesting that endothelial p53 modulates glucosermal chow (Chow) or a high-fat/high-sucrose (HFHS) diet (n = 5–10). *p < 0.05,
l-Chow versus Control-HFHS; #p < 0.05, EC-p53KO-Chow versus EC-p53KO-
littermate control after 8 weeks on the HFHS diet.
mined in 12-week-old mice as prepared in Figure 2A (chow: n = 6, B; HFHS:
n the HFHS diet. The graph shows percent of fat tissue/bodyweight for visceral
diet (n = 5).
ttermate controls (Control) on a normal chow (Chow) or a high-fat/high-sucrose
e HFHS diet. The graph indicates average oxygen consumption during the light
controls (Control) on the HFHS diet (n = 7).
nd littermate controls (Control) on the HFHS diet (n = 14). *p < 0.05, **p < 0.01.
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Figure 4. Endothelial p53 Upregulates the
Expression of PTEN that Downregulates
the Akt-eNOS Pathway
(A) Expression of p53, PTEN, phospho-eNOS,
eNOS, phospho-Akt, and Akt were examined by
western blot analysis in HUVECs infected with
adenovirus encoding LacZ (Ad-LacZ) or p53 (Ad-
p53) and transfected with siRNA-targeting PTEN
(siPTEN) or control siRNA (siControl). HUVECs
were cultured in growth factor-free medium for
24 hr and were harvested after stimulation for 1 hr
with growth factors (hEGF, hFGF-B, VEGF, and
R3-IGF-1).
(B) Quantitative analysis of expression of PTEN
protein levels in HUVECs infected with Ad-LacZ or
Ad-p53 (n = 3).
(C andD) Quantitative analyses of phosphorylation
levels of Akt (C) and eNOS (D) in HUVECs as
prepared in Figure 4A (n = 4). *p < 0.05, **p < 0.01,
***p < 0.001. Data are shown as the means ± SEM.uptake by skeletal muscle through regulation of Glut1 expres-
sion in endothelial cells.
Histological examination showed that Glut1 was predomi-
nantly expressed by the endothelium, with its expression being
markedly decreased whenmice were fed a high-calorie diet (Fig-
ure S5C). This decrease of Glut1 expression was attenuated in
EC-p53 KO mice (Figure S5C). Although we could not exclude
the possibility that deletion of endothelial p53 might regulate
Glut1 expression by smooth muscle cells through non-cell-
autonomous mechanisms, these results indicated that endothe-
lial p53 mainly influences Glut1 expression in the endothelium.Figure 3. Influence of Endothelial p53 Activity on Mitochondrial Biogenesis in Skeletal Muscle
(A) Expression of phosphoendothelial NO synthase (eNOS) and eNOS were examined by western blot analys
controls (Control) after 8 weeks on a normal chow (Chow) or a high-fat/high-sucrose (HFHS) diet (n = 3).
(B) Expression of p53, phospho-eNOS, and eNOS were examined by western blot analysis in HUVECs infecte
(Ad-p53) (n = 3).
(C) HUVECs as prepared in Figure 3B were treated with S-Nitrosoglutathione (GSNO), an NO donor, or vehicle
was examined by real-time PCR (n = 3).
(D) Real-time PCR analysis assessing expression of Ppargc1a (Pgc-1a) in the skeletal muscle of mice as pre
(E) Mitochondria DNA contents in the skeletal muscle of mice as prepared in Figure 3A (n = 5).
(F and G) Real-time PCR assessing expression of Ppargc1a (Pgc-1a) (F) andmitochondria DNA contents (G) in
EC-p53 KO mice, eNOS hetero knockout mice (Control-eNOS+/), and EC-p53-eNOS double knockout mice
**p < 0.01, ***p < 0.001.
(H) Glucose tolerance test (GTT) and insulin tolerance test (ITT) were examined in 12-week-old mice as pre
Control versus EC-p53KO; yp < 0.05, Control versus Control-eNOS+/; #p < 0.05, ##p < 0.01, EC-p53KO ve
means ± SEM.
Cell Reports 7, 1691–170Presumably, endothelial p53 would be
even more important for regulating Glut1
expression in skeletal muscle capillaries,
which only have a few pericytes.
Overexpression of p53 by
Endothelial Cells Exacerbates
Insulin Resistance and Fat
Accumulation
The activity of p53 is tightly regulated and
immediately diminishes in the absence of
critical stress to avoid unwanted conse-quences. Mdm2 and Mdm4 have been identified as negative
regulators of p53, and their essential role in the regulation of
p53 expression has been demonstrated in a variety of genetic
mouse models (Wade et al., 2010). To test whether upregulation
of endothelial p53 causes metabolic abnormalities, we estab-
lished endothelial cell-specific Mdm4 KO (EC-Mdm4 KO) mice
(Pdgfb-Cre-ER; Mdm4loxP/loxP) on a high-calorie diet. In this
model, expression of Mdm4 was deleted in the vascular
endothelium by treatment with tamoxifen, leading to upregula-
tion of endothelial p53 expression (Figures 6A and 6B). We
initially attempted to establish mice with endothelial cell-specifices in the aortas of EC-p53 KO mice and littermate
d with adenovirus encoding LacZ (Ad-LacZ) or p53
. Expression of Ppargc1a (Pgc-1a),Nrf1, and Tfam
pared in Figure 3A (n = 5).
the skeletal muscle of littermate controls (Control),
(EC-p53KO-eNOS+/) on the HFHS diet. *p < 0.05,
pared in Figure 3F (n = 4–6). *p < 0.05, **p < 0.01,
rsus EC-p53KO-eNOS+/. Data are shown as the
3, June 12, 2014 ª2014 The Authors 1697
Figure 5. Effect of Endothelial p53 Activity on Glucose Transport into Skeletal Muscle
(A) Real-time PCR assessing expression of Slc2a4 (Glut4) in the skeletal muscle of EC-p53 KO mice and littermate controls (Control) on the HFHS
diet (n = 8).
(B) Real-time PCR analysis assessing expression of SLC2A1 (GLUT1) in HUVECs infected with adenovirus encoding LacZ (Ad-LacZ) or p53 (Ad-p53) (n = 3).
(C) Relative glucose transport index was measured in HUVECs cultured under the normal or high-glucose condition (n = 3) as described in the Experimental
Procedures.
(D) Relative glucose transport index in HUVECs transfected with siRNA-targeting p53 or GLUT1 (n = 3).
(E) Real-time PCR analysis for Slc2a1 (Glut1) of the aorta of EC-p53 KOmice and littermate controls (Control) on a normal chow (Chow) or a high-fat/high-sucrose
(HFHS) diet (n = 5).
(F) Glucose uptake by skeletal muscle in lower extremities of EC-p53 KO mice and littermate controls (Control) on the HFHS diet treated with siRNA-targeting
Glut1 or control siRNA (n = 5–10). *p < 0.05, **p < 0.01. Data are shown as the means ± SEM.deletion of Mdm4 by using noninducible Tie2-Cre mice, but
we failed to obtain adult Tie2-Cre; Mdm4loxP/loxP mice, presum-
ably due to lethality of this deletion during embryonic develop-
ment. In contrast to EC-p53 KO mice, phosphorylation of
eNOS in the aorta and Pgc-1a expression in the skeletal
muscle were significantly reduced in EC-Mdm4 KO mice
compared with their control littermates (Figures 6B and 6C).
Likewise, endothelial Glut1 expression was markedly downre-
gulated in EC-Mdm4 KO mice (Figure 6D). Consequently,
insulin sensitivity and glucose tolerance were significantly
impaired by endothelial p53 activation (Figure 6E). We also
found that dietary obesity and fat accumulation were exacer-1698 Cell Reports 7, 1691–1703, June 12, 2014 ª2014 The Authorsbated in EC-Mdm4 KO mice compared with their control
littermates (Figures 6F and 6G), even though there was no
difference in food intake between the two groups (Figure 6H).
We noted that expression of Ppargc1a in skeletal muscle
was significantly decreased as early as 5 weeks after p53 acti-
vation in the endothelium, followed by upregulation of proin-
flammatory cytokine expression in fat tissue of EC-Mdm4 KO
mice (Figures S6A and S6B). These results suggest that
endothelial p53 activation decreases mitochondrial biogenesis
in skeletal muscle, leading to fat accumulation and inflamma-
tion, and exacerbates metabolic abnormalities associated
with obesity.
Figure 6. Upregulation of Endothelial p53 Exacerbates Metabolic Abnormalities
(A) Real-time PCR assessing expression ofMdm4 in the lungs of EC-Mdm4 KO mice and littermate controls (Control) on a high-fat/high-sucrose (HFHS) (n = 5).
(B) Expression of p53, phospho-eNOS, and eNOS was examined by western blot analyses in the aortas of mice as prepared in Figure 6A (n = 3).
(C and D) Real-time PCR assessing expression of Ppargc1a (Pgc-1a) in the skeletal muscle (C) and Slc2a1 (Glut1) in the aorta of mice (D) in 16-week-old mice
(8 weeks after gene deletion) prepared in Figure 6A (n = 4–6).
(E) Glucose tolerance test (GTT) and insulin tolerance test (ITT) were examined in 16-week-old mice prepared in Figure 6A (n = 7).
(F–H) Body weight (F), CT analysis (G), and food intake (H) of 16-week-old mice as prepared in Figure 6A (n = 5–7). *p < 0.05. Data are shown as themeans ± SEM.DISCUSSION
Alterations of the metabolic state could directly affect the func-
tion of vascular cells via the bloodstream. Endothelial cells exist
throughout the vascular system from the great vessels to the
capillaries and regulate the tissue microenvironment by produc-
ing various molecules, such as nitric oxide and inflammatory
cytokines. We observed upregulation of p53 protein expression
in various organs/tissues (particularly highly vascular organs) of
mice fed a high-calorie diet. We found that the increased ex-
pression of p53 was localized to the endothelium and that this
change accelerated the onset of metabolic abnormalities, suchCas obesity and insulin resistance, by reducing energy expendi-
ture and glucose transport. Inhibition of endothelial p53 attenu-
ated fat accumulation and inflammation, leading to improvement
of insulin resistance inmice fed a high-calorie diet. Our results do
not exclude the possibility that endothelial p53 regulates micro-
vascular perfusion but rather provide an additional insight into
how excessive calorie intake promotes vascular dysfunction
and thereby induces metabolic abnormalities.
The transcriptional coactivator PGC-1a was first identified
through its interaction with nuclear receptor peroxisome prolifer-
ator-activated receptor-g in brown adipose tissue and was
found to regulate adaptive thermogenesis (Puigserver et al.,ell Reports 7, 1691–1703, June 12, 2014 ª2014 The Authors 1699
1998). Recent evidence suggests that PGC-1a may have a crit-
ical role in skeletal muscle regulation by modulating a number of
gene expression programs (Arany, 2008), including those for
mitochondrial biogenesis, angiogenesis, and fiber composition.
It has been reported that PGC-1a modulates skeletal adapta-
tions by interacting with various transcription factors, such as
NRF-1, NRF-2, the estrogen-related receptors, and myocyte
enhancer factor-2 (Arany, 2008). Consistent with our results,
forced expression of Pgc-1a in skeletal muscle was reported
to increase oxidative type I fibers along with increased expres-
sion of mitochondrial markers in mice (Lin et al., 2002).
Conversely, Pgc-1a-deficient mice have fewer mitochondria
and a lower respiratory capacity in oxidative skeletal muscle
(Leone et al., 2005). Furthermore, Pgc-1a-deficient mice show
striking failure to restore limb blood flow after an ischemic insult,
whereas transgenic expression of Pgc-1a in skeletal muscle has
a protective effect (Arany et al., 2008). In contrast, we did not find
any changes of vessel density or expression of proangiogenic
factors in the skeletal muscle of EC-p53 KO mice, presumably
because NO-induced upregulation of Pgc-1a has different tran-
scriptional effects.
Although expression of PGC-1a and mitochondrial genes is
coordinately repressed in the skeletal muscles of diabetic
patients (Mootha et al., 2003; Patti et al., 2003), the role of skel-
etal muscle PGC-1a in insulin resistance remains equivocal. For
example, mice with Pgc-1a overexpression in skeletal muscle
are not sensitized to insulin signaling (Calvo et al., 2008; Miura
et al., 2003), although upregulation of Pgc-1a in skeletal muscle
is associated with improvement of insulin sensitivity in various
genetic models (Iwabu et al., 2010; Oike et al., 2005). It is note-
worthy that the expression of Glut4 was significantly downregu-
lated in mice with overexpression of Pgc-1a in skeletal muscle.
Thus, increasing Pgc-1a expression by transgenic intervention
could have unfavorable effects andmay not improve glucose ho-
meostasis in diabetic models. In our study, we found that disrup-
tion of endothelial p53 increased glucose uptake by upregulating
endothelial Glut1 expression, whereas skeletal muscle expres-
sion of Glut4 was unchanged. Hence, endothelial p53 activity
may affect various pathways involved in glucose homeostasis
rather than simply increasing PGC-1a expression.
We found that p53 plays a critical role in glucose homeostasis
by regulating the expression of genes, such as PTEN and
SLC2A1, presumably through its action as a transcription factor.
It is possible that p53 also regulates the expression of various
molecules secreted by the vascular endothelium and media,
which could influence the metabolism of neighboring cells via a
paracrine mechanism. Angiogenesis and vascular functions
have been shown to modulate obesity and adipose metabolism
(Cao, 2013), which could be involved in endothelial p53-induced
insulin resistance. Because overexpression of p21 has been re-
ported to alter the expression of various genes, including proin-
flammatory cytokines (Kunieda et al., 2006; Miyauchi et al.,
2004), it is also conceivable that upregulation of p21 expression
by a high-calorie diet had an additional influence on glucose
homeostasis in our model.
It is generally accepted that the endothelium does not play a
rate-limiting role in glucose metabolism. However, there is evi-
dence suggesting that Glut1 has a rate-limiting role in deter-1700 Cell Reports 7, 1691–1703, June 12, 2014 ª2014 The Authorsmining endothelial glucose transport in an insulin-independent
manner (Alpert et al., 2005; Huang et al., 2012; Rajah et al.,
2001). For example, Huang et al. (2012) reported that a decrease
of Glut1 expression by endothelial cells in mice reduces glucose
uptake into various tissues, including the heart, leading to
impaired glucose clearance and glucose intolerance. In the pre-
sent study, we found that a high-calorie diet downregulated
Glut1 expression in endothelial cells in association with the upre-
gulation of p53 expression, whereas the deletion of endothelial
p53 inhibited diet-induced downregulation of Glut1 expression
and improved glucose uptake by skeletal muscle. For analysis
of glucose uptake in mice, we used a minimal dose of 2-deoxy-
glucose that did not stimulate insulin secretion, so our results
demonstrate a role of endothelial Glut1 in insulin-independent
glucose transport.
In conclusion, our results indicate that endothelial p53 regu-
lates glucose metabolism by modulating mitochondrial biogen-
esis and glucose uptake into skeletal muscle. There is evidence
that features of the diabetic state, such as hyperglycemia and
hyperinsulinemia, lead to upregulation of endothelial p53 expres-
sion through mechanisms involving an increase of oxidative
stress and activation of stress-response kinases, thus promoting
the development of cardiovascular complications (Chen and
Goligorsky, 2006; Minamino and Komuro, 2007, 2008). The pre-
sent findings demonstrate the mechanism of a vicious cycle in
which upregulation of endothelial p53 induces metabolic abnor-
malities that in turn promote cardiovascular dysfunction. Inhibi-
tion of endothelial p53 could be a new therapeutic strategy for
blocking this vicious circle in obese patients.
EXPERIMENTAL PROCEDURES
Animal Models
All animal study protocols were approved by the Chiba University review
board. C57BL/6 mice were purchased from the SLC Japan. Mice were fed a
high-fat/high sucrose (HF/HS) diet (Maeda et al., 2002) or normal chow from
4 to 12 weeks of age before metabolic analyses were performed. Mice that
expressed Cre recombinase in endothelial (Tie2-Cre) were purchased from
Jackson Laboratories. We then crossed Tie2-Cre mice (with a C57BL/6 back-
ground) with mice that carried floxed Trp53 alleles (with a C57BL/6 back-
ground) (Marino et al., 2000) to generate endothelial cell-specific p53 knockout
mice. These mice used in this study were 12–14 weeks old. To inhibit NOS
activity, we crossed endothelial cell-specific p53 knockout mice with eNOS
knockout mice that were purchased from Jackson Laboratories to establish
endothelial cell-specific p53 and eNOS double knockout mice. We also
crossed Pdgfb-Cre-ER mice (with a C57BL/6 background) (Claxton et al.,
2008) with mice that carried floxed Trp53 alleles or floxed Mdm4 alleles (with
a C57BL/6 background) (Grier et al., 2006) to generate other endothelial cell-
specific p53 knockout mice or endothelial cell-specific Mdm4 knockout
mice. These mutant mice received 10 mg kg1 of tamoxifen (Sigma-Aldrich)
intraperitoneally once a day for 5 consecutive days at 8 weeks of age to induce
Cre-mediated recombination and were fed the HF/HS diet afterward. After
5–10 weeks, they were analyzed for metabolic parameters.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were grown in EBM-2 me-
dium (Lonza) with 2% FBS, growth factors (hEGF, hFGF-B, VEGF, and R3-
IGF-1), heparin, hydrocortisone, ascorbic acid, and antibiotics (50mg ml1
gentamicin and 50 mg/ml amphotericin B). To examine the effects of exposure
to high glucose or palmitic acid, HUVECs were cultured in the medium with
30 mM glucose or 500 mM palmitic acid for 24 hr before harvesting. Palmitic
acid stock solution (5mM)waspreparedbyconjugationwithBSA, asdescribed
previously (Cousin et al., 2001). For the control, 5mMglucosewas added to the
basal medium, and D-mannitol and BSA solution were also added to adjust the
osmotic pressure. Growth factors were not added during exposure to high
glucose or palmitic acid. C2C12 mouse myoblasts were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% serum. To induce dif-
ferentiation into myotubes, C2C12 myoblasts were cultured in DMEMwith 2%
serum. The coculture assay system was established by using 24-well cell cul-
ture inserts (0.4mmpore size; BDFalcon). HUVECs andC2C12were seeded on
outer well and insert membrane, respectively. S-Nitrosoglutathione (GSNO,
5 mM; Sigma) was used as an NO donor to evaluate the effect of NO.
Physiological Analyses
We housedmice individually andmonitored their body weight and food intake.
The adiposity of mice was examined using CT (LaTheta, ALOCA) in accor-
dance with the manufacturer’s protocol. We performed computed tomogra-
phy scanning at 2 mm intervals from the diaphragm to the floor of the
abdominal cavity. Oxygen consumption was measured by using an O2/CO2
metabolic measurement system (model MK-5000; Muromachikikai) as
described previously (Oike et al., 2005). The core body temperature and
activity of mice were measured by using implantable intra-abdominal radiofre-
quency probes and receivers (TA10TA-F20 and RPC-1; Data Sciences Inter-
national) (Barber et al., 2004). The data were sampled in a continuous mode
and analyzed by Dataquest ART2.1. Blood flow in skeletal muscle was
measured with a laser Doppler perfusion analyzer (moorLDI2-IR; Moor Instru-
ments) in lower limbs denuded of skin.
Laboratory Tests
For the intraperitoneal glucose tolerance test, mice were fasted overnight and
were given glucose at a dose of 1 g kg1 (bodyweight). For the insulin tolerance
test, mice were given human insulin intraperitoneally (1 U kg1 body weight).
Tail vein blood was collected at 0, 15, 30, 60, and 120 min after administration,
and blood glucose levels were measured with Antisense III (HORIBA), whereas
plasma insulin levels were measured by insulin immunoassay (Morinaga).
Viral Infection and Transfection
Small interfering RNA (siRNA)-targeting p53 or Glut1 was purchased from
Invitrogen (designed by BLOCK-iT RNAi Designer) and introduced into human
endothelial cells by using Lipofectamine RNAiMax (Invitrogen) in accordance
with the manufacturer’s instructions. High-titer adenoviral stocks (109 pla-
que-forming units) were generated with the Adeno-X Expression System
(Clontech) in accordance with the manufacturer’s instructions.
Statistical Analysis
Data are shown as the mean ± SEM. Differences between groups were exam-
ined by Student’s t test or ANOVA followed by Bonferroni’s correction for
comparison of means. For all analyses, p < 0.05 was considered statistically
significant.
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